Healthy volunteers test new drug VNRX-5024 in early safety study
NCT ID NCT04314206
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety of a new drug called VNRX-5024 in 36 healthy adults aged 18-55. Participants received either the drug or a placebo, first as a single dose and then daily for 10 days. The main goal was to check for side effects and measure how the drug moves through the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
PRA Health Sciences - Early Development Services
Groningen, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer reveals the Body's journey of an experimental drug
- Can music lessons rewire Teens' social media habits?
- Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Sound waves as medicine: ultrasound may tame inflammation without drugs
- Broader pneumonia shield: new vaccine tested in children